Positive commentary with dasotraline for ADHD in children ages 6-12
Robert Goldman, PhD, Sunovion Pharmaceuticals (Marlborough, MA and Fort Lee, NJ), and colleagues from Kennedy Krieger Institute/Johns Hopkins University (Baltimore, MD), New York University Langone Medical Center (New York, NY), and Massachusetts General Hospital (Boston, MA) coauthored a essay entitled �Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.�
Related Bookmarks
- A gut feeling for mental health
- Teens too low on sleep, activity, and too high on shade time
- Flu May Raise Chance of Stroke, Neck Artery Tears
- Tyson Foods Recalls Chicken Nuggets
- Why Sleepless Nights Can Mean More Painful Days
- Big Gains Vs Hep C Possible With Big Investment
- Can Strict BP Control Lower Your Dementia Risk?
- Simply resplendent light on ‘dinosaur metal’ devalue kills cancer cells
- Mapping esophageal cancer genes leads to new drug targets
- Obesity-related cancers rising in immature adults in a US
Recent Profiles
Lucky88app6
Giaimanhacai 01io
Gpdrcompliant3
Nha Dat
Canan
All About Recliners
Levittown Concrete
Vijay Bandaru
Fabet Brcom
Tr88 Barcelona